These findings have been explored using ANXA1 N-terminal mimetic peptide Ac2-26, which has shown promising value as an anticancer agent through the inhibition of cervical cancer cell proliferation [197] and modulation of the NF-κB signaling pathway in lung cancer [198]. This evidence concerns the gene ANXA1 and lung carcinoma.